BioAtla (NASDAQ:BCAB) Stock Price Down 1.7% – What’s Next?

BioAtla, Inc. (NASDAQ:BCAB)’s stock price was down 1.7% during mid-day trading on Friday . The stock traded as low as $3.89 and last traded at $3.9210. Approximately 6,513 shares were traded during trading, a decline of 89% from the average session volume of 60,562 shares. The stock had previously closed at $3.99.

Analyst Ratings Changes

Several brokerages have weighed in on BCAB. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of BioAtla in a research report on Wednesday, June 3rd. Wall Street Zen raised shares of BioAtla to a “hold” rating in a research report on Saturday, April 11th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $200.00.

BioAtla Stock Performance

The stock has a 50 day moving average of $3.83 and a two-hundred day moving average of $8.32. The firm has a market capitalization of $6.51 million, a P/E ratio of -0.09 and a beta of 0.76.

BioAtla (NASDAQ:BCAB) last announced its earnings results on Friday, May 15th. The company reported ($4.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($10.00) by $5.78.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of BCAB. Woodline Partners LP bought a new stake in BioAtla during the first quarter valued at about $26,000. ADAR1 Capital Management LLC grew its position in shares of BioAtla by 24.6% in the first quarter. ADAR1 Capital Management LLC now owns 228,107 shares of the company’s stock valued at $37,000 after purchasing an additional 45,000 shares during the last quarter. Susquehanna International Group LLP increased its stake in shares of BioAtla by 237.6% in the third quarter. Susquehanna International Group LLP now owns 252,583 shares of the company’s stock worth $174,000 after purchasing an additional 177,760 shares during the period. Jane Street Group LLC increased its stake in shares of BioAtla by 55.4% in the fourth quarter. Jane Street Group LLC now owns 346,774 shares of the company’s stock worth $197,000 after purchasing an additional 123,597 shares during the period. Finally, Millennium Management LLC acquired a new position in shares of BioAtla during the 3rd quarter worth about $235,000. Institutional investors and hedge funds own 77.23% of the company’s stock.

About BioAtla

BioAtla, Inc (NASDAQ: BCAB) is a clinical‐stage biotechnology company focused on the development of conditionally active biologics (CABs) for oncology and other serious diseases. Utilizing its proprietary CAB technology platform, BioAtla engineers monoclonal antibodies, bispecifics and antibody-drug conjugates that remain inactive in healthy tissues but become activated in the tumor microenvironment. This targeted approach aims to improve therapeutic index by enhancing anti‐tumor potency while minimizing off-target effects and systemic toxicity.

Founded in 2012 and headquartered in San Diego, California, BioAtla has advanced multiple product candidates into clinical trials.